文献速递肝病

肝硬化非急性失代偿的临床与病理生理特征

Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis.
PubMed 文献 · J Hepatol · 2025-03-07

这项前瞻性研究在印度两个中心纳入代偿期肝硬化29例、非急性失代偿(NAD)311例、急性失代偿(AD)201例及健康对照10例,评估细胞因子与细胞死亡标志物。NAD的12个月生存率81.7%,低于代偿期肝硬化的100%但高于AD的31.2%;NAD进展为AD的12个月累积发生率为55.1%,进展者生存率68.2% vs 未进展者95.3%。

要点

  • NAD的12个月生存率81.7%,介于代偿期肝硬化(100%)与AD(31.2%)之间(p<0.001)。
  • NAD患者虽有细胞死亡标志物升高,但无显著全身炎症,标志物在AD中最明显。
  • NAD进展为AD的12个月累积发生率为55.1%,进展者生存率显著降低(68.2% vs 95.3%)。

核心结论

  • NAD在临床、预后和病理生理上是肝硬化中一个独立的实体,患者细胞死亡标志物升高,仍存在进展为AD和死亡的风险。
  • 识别进展为AD和死亡的高危患者应促使采取干预措施以预防进展,调节细胞死亡是肝硬化中一个潜在的疾病修饰靶点。

研究设计与样本

  • 前瞻性研究,2020至2023年从印度两个中心纳入代偿期肝硬化29例、NAD 311例、AD 201例及健康对照10例。
  • 基线评估临床和实验室参数、细胞因子(IL-6、TNF、IL-10、MCP-1)及细胞死亡标志物(M30、M65、Gasdermin-D、RIPK3、MLKL),随访12个月评估总生存。
  • 在NAD患者中评估进展为AD和死亡的预测因素。

主要发现

  • NAD的12个月生存率81.7%,低于代偿期肝硬化的100%,但高于AD的31.2%(p<0.001)。
  • NAD患者无显著全身炎症,但细胞死亡标志物(尤其是Gasdermin-D和RIPK3)水平高于健康对照和代偿期肝硬化患者。
  • 炎症和细胞死亡标志物在AD中最明显。
  • NAD患者12个月内进展为AD的累积发生率为55.1%,进展者生存率68.2% vs 未进展者95.3%(p<0.001)。

关键数值与推荐

  • 进展为AD的预测因素包括严重腹水、较低IGF-1、白蛋白、BMI,较高胆红素、Gasdermin-D、RIPK3水平,以及较高CTP和MELD评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The heterogenous presentation patterns in decompensated cirrhosis confer variable outcomes. While acute decompensation (AD) is well-characterized, the presentation patterns and outcomes of non-acute decompensation (NAD) remain unclear. The aim of this study was to characterize clinical and pathophysiological features of NAD and identify predictors of progression in NAD. METHODS: In this prospective study, patients across the cirrhosis spectrum were enrolled from two centers in India between 2020-2023: compensated cirrhosis (CC; n = 29), NAD (n = 311), AD (n = 201), and healthy controls (n = 10). Clinical and laboratory parameters, cytokine levels (IL-6, TNF, IL-10, MCP-1) and cell death markers (M30, M65, Gasdermin-D, RIPK3, MLKL) were assessed at baseline. Twelve-month overall survival was assessed in all patients. The predictors of progression to AD and mortality were evaluated in patients with NAD. RESULTS: Survival was lower in patients with NAD (81.7%) than in those with CC (100%), but higher than in those with AD (31.2%) (p <0.001). Despite no significant systemic inflammation, patients with NAD exhibited elevated levels of cell death markers, particularly Gasdermin-D and RIPK3, compared to healthy controls and patients with CC. Both inflammatory and cell death markers were most pronounced in AD. Over 12 months, the cumulative incidence of progression to AD among those with NAD was 55.1%, significantly reducing their survival (68.2% vs. 95.3%, p <0.001). Predictors of such progression to AD included severe ascites, lower IGF-1, albumin, BMI, and higher bilirubin, Gasdermin-D, and RIPK3 levels, as well as higher CTP and MELD scores. CONCLUSIONS: NAD represents a clinically, prognostically and pathophysiologically distinct entity in cirrhosis. Patients with NAD express elevated cell death markers and remain at risk of progression to AD and mortality. Identifying such high-risk patients should prompt interventions to prevent progression. Modulation of cell death is a potentially disease-modifying target in cirrhosis. IMPACT AND IMPLICATIONS: This study highlights non-acute decompensation as a clinically, prognostically and pathophysiologically distinct subset of cirrhosis, underscoring the importance of understanding its progression dynamics. Identifying key predictors of acute decompensation, including ascites severity, low IGF-1 levels, and elevated cell death markers, such as Gasdermin-D and RIPK3, potentially uncovers new therapeutic avenues. These findings are crucial for helping hepatologists and researchers to risk stratify patients and optimize transplant candidacy. Interventions targeting necroptosis and pyroptosis pathways may improve outcomes, providing a significant shift towards precision medicine in cirrhosis care.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Verma N, Kaur P, Garg P, et al. Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis. J Hepatol. 2025. PMID: 40056937. doi:10.1016/j.jhep.2025.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。